Preventing Disability from Dupuytren’s Contracture with Dr. Jim Woody 180 Life Sciences

Published: Dec. 15, 2020, 7:54 p.m.

Dr. Jim Woody, CEO, 180 Life Sciences is one of four world-renowned scientists that have come together to form 180 LS to focus on treating inflammation, fibrosis and pain. Jim discusses the company's lead clinical program using anti-TNF to treat Dupuytren's contracture, a fibrotic disease of the hand. With a goal of preventing the fibrosis, Jim is drawing on his early invention of the first anti-TNF drug that worked in rheumatoid arthritis, Crohn's disease and psoriasis with an eye to preventing frozen shoulder as well.

#fibrosis #inflammation #Dupuytren #antiTNF

180LifeSciences.com

Download the transcript here

180 Life Sciences